Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment

There is no consensus on the optimal treatment for patients with advanced non-small-cell lung cancer (NSCLC) and stable disease (SD) after gefitinib therapy. This randomized, open-label, multicenter study aimed to explore whether dose-escalation of gefitinib would improve response and survival in NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Cong, Hong, Shaodong, Li, Ning, Feng, Weineng, Jia, Jun, Peng, Jiewen, Lin, Daren, Cao, Xiaolong, Wang, Siyang, Zhang, Weimin, Zhang, Hongyu, Dong, Wei, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516974/
https://www.ncbi.nlm.nih.gov/pubmed/26216071
http://dx.doi.org/10.1038/srep10648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516974/
https://www.ncbi.nlm.nih.gov/pubmed/26216071
http://dx.doi.org/10.1038/srep10648

Ejemplares similares